With its technology, the company hopes to connect more cancer patients being treated in community-based practices to beneficial clinical trials based on genomic biomarkers.
The researchers are taking a transcriptome-wide approach to identifying and validating common genes that affect genetic risk in both breast and ovarian cancers.
The LOHGIC algorithm is currently being used to analyze tumor sequencing assay results as part of the Rutgers Cancer Institute's precision medicine program.
The partners will integrate genomic, imaging, and other data to identify new therapies and personalize treatments for patients with neurological and neurodegenerative diseases.
A study of gene expression data from 173 breast cancer patients identified subtype-specific associations between molecular processes in tumor and blood cells.
The British CRISPR software developer is turning to investment platform SyndicateRoom as it looks to commercialize its products and expand into the US.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
